Pasithea Therapeutics Corp. (NASDAQ:KTTA) Sees Large Increase in Short Interest

Pasithea Therapeutics Corp. (NASDAQ:KTTA – Get Free Report) was the target of a large increase in short interest during the month of October. As of October 30th, there was short interest totaling 386,722 shares, an increase of 121.5% from the October 15th total of 174,598 shares. Approximately 1.2% of the company’s shares are sold short. Based on an average daily trading volume, of 459,545 shares, the short-interest ratio is currently 0.8 days.

Institutional Trading of Pasithea Therapeutics

A hedge fund recently bought a new position in Pasithea Therapeutics stock. Renaissance Technologies LLC acquired a new stake in Pasithea Therapeutics Corp. (NASDAQ:KTTA – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 93,399 shares of the company’s stock, valued at approximately $69,000. Renaissance Technologies LLC owned 0.37% of Pasithea Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 23.92% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on KTTA shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pasithea Therapeutics in a report on Monday, September 21st. Zacks Research lowered Pasithea Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 17th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $3.00.

Get Our Latest Research Report on Pasithea Therapeutics

Pasithea Therapeutics Price Performance

Shares of KTTA stock opened at $0.52 on Monday. The stock has a market cap of $17.44 million, a price-to-earnings ratio of -0.38 and a beta of 0.39. Pasithea Therapeutics has a fifty-two week low of $0.28 and a fifty-two week high of $2.06. The firm’s 50 day moving average price is $0.48 and its two-hundred day moving average price is $0.61.

Pasithea Therapeutics (NASDAQ:KTTA – Get Free Report) last released its quarterly earnings data on Friday, November 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.01. On average, equities analysts forecast that Pasithea Therapeutics will post -0.76 EPS for the current fiscal year.

About Pasithea Therapeutics

(Get Free Report)

Pasithea Therapeutics is a clinical-stage biotechnology company developing therapies for serious diseases. Its current focus is PAS-004, a next-generation macrocyclic MEK inhibitor being studied for conditions associated with the RAS/MAPK signaling pathway, including neurofibromatosis type 1. The company’s research has shifted over time: Pasithea previously focused on treatments for neurological and psychiatric disorders. Its current development efforts are centered on PAS-004 and potential applications in diseases with limited treatment options.

See Also

Receive News & Ratings for Pasithea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pasithea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.